New pediatric dosing recommendations for atazanavir.
D000293:Adolescent; D000328:Adult; D000069446:Atazanavir Sulfate; D002214:Capsules / Q000008:administration & dosage / Q000592:standards; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004348:Drug Labeling; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000592:standards; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D007223:Infant; D015337:Multicenter Studies as Topic; D009842:Oligopeptides / Q000008:administration & dosage / Q000592:standards; D011725:Pyridines / Q000008:administration & dosage / Q000592:standards; D012015:Reference Standards; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D002214:Capsules; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D000069446:Atazanavir Sulfate